Michael Barbella, Managing Editor05.03.22
Dyad Medical Inc. has joined the TMU x BE Accelerator Program, giving the cardiac imaging platform startup leverage in international markets as the company scales and grows its digital health solutions.
“Dyad Medical is thrilled to be selected for the TMU x BE Accelerator Program as we continue to expand into new markets with confidence, especially after Libby™ IAAA (Intravascular Automated Analysis Application) received FDA clearance,” said Ronny Shalev, Ph.D., CEO and co-founder of Dyad Medical. “TMU x BE Accelerator understands the complexities of the healthcare industry but also recognizes the potential for innovation which is something that excited us about the program.”
Dyad Medical’s cardiac imaging analysis app is powered by AI, an area of focus for TMU x BE Accelerator. The system learns from the collective insights of multiple experts using millions of past cardiac images, results, observations, and conclusions. This drives the analysis and interpretation of new cardiac images. Dyad Medical’s solution guides a cardiologist in the interpretation of a case. It expands the physicians’ view, so they have greater confidence in their diagnosis, leading to greater patient satisfaction and retention. It also enables researchers to draw more accurate conclusions efficiently.
BE Accelerator focuses exclusively on Healthtech and Medtech, supporting startups with access to hospital facilities, research institutes, investors, health experts and other healthcare industry stakeholders. Dyad Medical’s participation in the program includes access to Taipai Medical University’s world-class hospitals’ medical research and data and physicians’ insights which will enhance its AI-powered platform.
“TMU x BE Accelerator’s strong relationships within the international healthcare industry will give Dyad Medical traction in new markets. This allows us to further our mission of enabling clinicians to provide high quality healthcare efficiently and accurately from anywhere in the world,” added Dr. Shalev.
Boston-based Dyad Medical develops clinical applications using cloud-based artificial intelligence aimed at enabling doctors to interpret medical image content more efficiently from anywhere in the world. It is powered by the expertise of a global community of clinicians who train the model, effectively offering practitioners “thousands of second opinions.” Within the digital diagnostics arena, Dyad Medical’s core focus is on cardiac imaging because more people die as a result of cardiovascular disease than all types of cancer, diabetes, and accidents combined.
BE Accelerator is the largest growth-focused program and venture builder for healthtech, medtech, and digital health startups in Taiwan. BE Accelerator backs startups looking to make an impact for the next 10 years and beyond. Based in Taipei, supported by leading hospital groups, and leverage the unique strengths of the country's ecosystem to position as the gateway to Asia for both local and international startups. Since 2018, BE Accelerator has incubated 72 healthcare ventures and helped them raise more than $100 million successfully. With access to hospital facilities, research institutes, investors, healthcare experts, and other industry stakeholders, BE Accelerator helps startups navigate the tricky healthcare landscape by closing the gap between ICT, healthcare, and business.
The TMU BIOMED Accelerator is the first international medical university accelerator in Taiwan with a medical market place, clinical advantages, biomedical and artificial intelligence talents. TMU BIOMED Accelerator focuses on digital health, artificial intelligence, and medical equipment for assisting startups, including raising funds, community and international resource linkage, coaching and reducing development risks, clinical trial planning, and establishing medical pathways.
“Dyad Medical is thrilled to be selected for the TMU x BE Accelerator Program as we continue to expand into new markets with confidence, especially after Libby™ IAAA (Intravascular Automated Analysis Application) received FDA clearance,” said Ronny Shalev, Ph.D., CEO and co-founder of Dyad Medical. “TMU x BE Accelerator understands the complexities of the healthcare industry but also recognizes the potential for innovation which is something that excited us about the program.”
Dyad Medical’s cardiac imaging analysis app is powered by AI, an area of focus for TMU x BE Accelerator. The system learns from the collective insights of multiple experts using millions of past cardiac images, results, observations, and conclusions. This drives the analysis and interpretation of new cardiac images. Dyad Medical’s solution guides a cardiologist in the interpretation of a case. It expands the physicians’ view, so they have greater confidence in their diagnosis, leading to greater patient satisfaction and retention. It also enables researchers to draw more accurate conclusions efficiently.
BE Accelerator focuses exclusively on Healthtech and Medtech, supporting startups with access to hospital facilities, research institutes, investors, health experts and other healthcare industry stakeholders. Dyad Medical’s participation in the program includes access to Taipai Medical University’s world-class hospitals’ medical research and data and physicians’ insights which will enhance its AI-powered platform.
“TMU x BE Accelerator’s strong relationships within the international healthcare industry will give Dyad Medical traction in new markets. This allows us to further our mission of enabling clinicians to provide high quality healthcare efficiently and accurately from anywhere in the world,” added Dr. Shalev.
Boston-based Dyad Medical develops clinical applications using cloud-based artificial intelligence aimed at enabling doctors to interpret medical image content more efficiently from anywhere in the world. It is powered by the expertise of a global community of clinicians who train the model, effectively offering practitioners “thousands of second opinions.” Within the digital diagnostics arena, Dyad Medical’s core focus is on cardiac imaging because more people die as a result of cardiovascular disease than all types of cancer, diabetes, and accidents combined.
BE Accelerator is the largest growth-focused program and venture builder for healthtech, medtech, and digital health startups in Taiwan. BE Accelerator backs startups looking to make an impact for the next 10 years and beyond. Based in Taipei, supported by leading hospital groups, and leverage the unique strengths of the country's ecosystem to position as the gateway to Asia for both local and international startups. Since 2018, BE Accelerator has incubated 72 healthcare ventures and helped them raise more than $100 million successfully. With access to hospital facilities, research institutes, investors, healthcare experts, and other industry stakeholders, BE Accelerator helps startups navigate the tricky healthcare landscape by closing the gap between ICT, healthcare, and business.
The TMU BIOMED Accelerator is the first international medical university accelerator in Taiwan with a medical market place, clinical advantages, biomedical and artificial intelligence talents. TMU BIOMED Accelerator focuses on digital health, artificial intelligence, and medical equipment for assisting startups, including raising funds, community and international resource linkage, coaching and reducing development risks, clinical trial planning, and establishing medical pathways.
